Supplementary Figure 1.

A.  

B.
C. Urinary Osteopontin

![Urinary Osteopontin Graph](graph.png)
Supplementary Figure 2.

A.

Urinary Albumin

Treatment Group

Vehicle (Saline)  CDDP (0.75 mg/kg/day)
B. Urinary Neutrophil Gelatinase-Associated Lipocalin

![Graph showing Urinary NGAL levels over time for different treatment groups. The x-axis represents time points (D6, D10, D15), and the y-axis represents Urinary NGAL levels in ng/mmol Ur Cr.}

- Vehicle (Saline)
- CDDP (0.75 mg/kg/day)

The graph illustrates the Urinary NGAL levels over a period of several days following different treatments, with the levels expressed in nanograms per millimolar of urinary creatinine.
Supplementary Figure 3.

A.  

B.  

C.  

D.  

E.  

F.
Supplementary Figure 3. (continued)

G.
Supplementary Figure 4.

[Image of a gel containing samples labeled G1-1 to G2-26, with markers for short exposure (5 min) and long exposure (10 min), and a note for Ur NGAL (23 kDa).]
**Supplementary Figure 5.**

**Cisplatin Beagle Dogs Feasibility Study Design**

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1: Vehicle</td>
<td>0.9% Saline for Injection (USP)</td>
</tr>
<tr>
<td>Group 2: Cisplatin (CDDP)</td>
<td>0.75 mg/kg/dose</td>
</tr>
<tr>
<td>Route of administration</td>
<td>IV slow infusion (~20 minutes)</td>
</tr>
<tr>
<td>Dosing regimen</td>
<td>Once daily/ 5 consecutive days</td>
</tr>
<tr>
<td>Non-naïve animals (fasted)</td>
<td>Male Beagle dogs (5-6/group)</td>
</tr>
<tr>
<td>Blood/urine collection(s)</td>
<td>Predose, D1-D6, D8, D10 and 15</td>
</tr>
<tr>
<td>Toxicologic pathology endpoints</td>
<td>Serum CDDP, blood/urine biomarkers, kidney histopathology and kidney immunohistochemical staining</td>
</tr>
</tbody>
</table>